This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Diabetes, Metabolic Syndrome And Cardiovascular Disease

TABLE OF CONTENTS

1. Overview 8

1.1 Statement of Report 8

1.2 About this Report 8

1.3 Scope of the Report 9

1.4 Methodology 9

1.5 Executive Summary 10

2. Introduction 152.1 Demographics of Diabetes 162.1.1 Worldwide Diabetes 162.1.2 U.S. Diabetes 182.2 Economics of Diabetes 21

3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 26

3.1 Pre-Diabetes Syndrome 27

3.2 Metabolic Syndrome 27

3.3 Diabetes and Inflammation 32

3.4 Diagnosis of Diabetes Mellitus 33

3.5 Progression of Diabetes 33

3.6 Risk Factors and Diabetes 33

3.6.1 Obesity 34

3.6.2 Stress-Induced Hyperglycemia 37

3.7 Complications and Co-Morbidities in Type 2 Diabetes 37

3.7.1 Preventing Complications and Co-Morbidities in Diabetes 40

3.8 Hypoglycemia Resulting from Treatment 41

3.9 Cardiovascular Disease (CVD) 41

3.9.1 CVD Facts 41

3.9.2 Cardiac Care Therapeutics 48

3.9.2.1 Anti-Hypertensive Drugs 49

3.9.2.2 Cholesterol Management Drugs 50

3.9.2.3 Anticoagulants 53

3.9.3 CVD Diagnostics 53

4. Pharmaceutical Industry and the Anti-Diabetes Market 564.1 The Worldwide Pharmaceutical Industry 564.1.1 Pharmaceutical R&D Spending by Type, Growth Rate and Expenditure 564.1.2 Global Pharmaceutical Market 584.2 Total Diabetes Drug Market Size and Growth 624.2.1 Sales of Anti-Diabetic Drugs Continue to Rise 654.3 Diabetic Medications Overview 664.3.1 Recent Trends in Diabetic Drug Usage 674.3.2 Market Influence Factors 71

5. Non-Insulin Anti-Diabetes Products 73

5.1 Anti-Diabetic Drug Therapy Overview 73

5.1.1 Sulfonylureas 77

5.1.2 Meglitinides 78

5.1.3 Biguanides 79

5.1.4 Thiazolidinediones (TZDs) 80

5.1.5 a-Glucosidase Inhibitors 82

5.1.6 Incretin Mimetics/Glucagon-like Peptide (GLP-1) Analogs and Agonists 83

5.1.6.1 Byetta (Exenatide) 84

5.1.6.2 Victoza (Liraglutide) 85

5.1.6.3 Bydureon (Exenatide LAR) 85

5.1.7 Amylin Analog 85

5.1.8 DPP-IV Inhibitors 86

5.1.8.1 Januvia (Sitagliptin) 86

5.1.8.2 Onglyza (Saxagliptin) 86

5.1.8.3 Tradjenta (Linagliptin) 86

5.1.8.4 Galvus (Vildagliptin) 87

5.1.9 Combination Therapy 87

5.1.9.1 Youth with Recent-Onset Type 2 Diabetes should be Started on Combination

Therapies 88

2 of 9

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs